Sage's depression drug met the main goal

Jose Verdugo
Diciembre 8, 2017

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cwm Llc owns 6 shares. Royal Bank Of Canada decreased their target price on Sage Therapeutics from $145.00 to $137.00 and set an "outperform" rating for the company in a research note on Monday, November 27th. State of Wisconsin Investment Board acquired a new position in Sage Therapeutics during the second quarter worth approximately $1,991,000. (NASDAQ:SAGE). Airain Ltd stated it has 0.06% of its portfolio in Sage Therapeutics, Inc. Mirae Asset Glob Invs accumulated 0.03% or 22,312 shares.

1,102 are owned by Quantbot Tech Limited Partnership. Ubs Asset Management Americas Inc owns 223,743 shares. Raymond James Associates reported 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE). Northwestern Mutual Wealth Management invested in 34 shares. Axa holds 0.02% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 67,872 shares. University Of Notre Dame Du Lac holds 0.82% or 34,936 shares in its portfolio. (NASDAQ:SAGE) hit a new 52-week high and has $165.55 target or 3.00 % above today's $160.73 share price. This indicates more upside for the $6.60B company. The 1-year high was reported on Dec, 7 by Barchart.com. An all time high points to a stock which has the most positive fundamentals ever.

The stock increased 75.05% or $68.97 during the last trading session, reaching $160.87. About 4.65 million shares traded or 445.81% up from the average.

Sage Therapeutics (SAGE) launched to a record high Thursday after unveiling data showing almost three-quarters of patients in a Phase 2 trial of its depression drug were in remission within 15 days. It has outperformed by 99.75% the S&P500.

More news: Los iPhone 2018 serán iguales al iPhone X

SAGE has been the topic of several other research reports. They expect $-2.00 EPS, down 33.33 % or $0.50 from last year's $-1.5 per share. Its down 0.13, from 1.11 in 2017Q1. (NASDAQ:SAGE). Emerald Advisers Pa holds 0.61% of its portfolio in Sage Therapeutics, Inc. Therefore 88% are positive. The stock has a consensus rating of "Buy" and an average price target of $121.86. SAGE Therapeutics had 45 analyst reports since September 3, 2015 according to SRatingsIntel. (NASDAQ:SAGE) rating on Friday, August 4. The company was maintained on Thursday, October 19 by SunTrust. Goldman Sachs initiated the shares of SAGE in report on Wednesday, March 30 with "Neutral" rating. The firm earned "Buy" rating on Tuesday, September 12 by Leerink Swann. On Friday, November 10 the stock rating was upgraded by Chardan Capital Markets to "Buy". Needham maintained the stock with "Buy" rating in Tuesday, June 13 report. Teacher Retirement System of Texas acquired a new position in shares of Sage Therapeutics in the second quarter valued at approximately $202,000. Visit MarketWatch.com for more information on this news.

Starting wth a market cap of $3.8 billion this morning, Sage saw its shares soar 67% after the latest round of results. (NASDAQ:SAGE) were released by: Realmoney.Thestreet.com and their article: "Sage Therapeutics Skyrockets on Data for Depression Drug - Biotech Movers" published on December 07, 2017 as well as Schaeffersresearch.com's news article titled: "SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout" with publication date: December 07, 2017.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The company's postpartum depression drug aced two key studies in November, paving the way for it to bring to market the first FDA-approved treatment for the disorder. The Company's lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus, as well as for the treatment of post-partum depression (PPD).

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO